Navigation Links
Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial

DENVER, March 3 /PRNewswire/ -- Pharmatech, Inc., a Research Management Organization (RMO), has contracted with Systems Medicine LLC (SML), a subsidiary of Seattle-based Cell Therapeutics, Inc. (CTI), to provide research and site management services for their phase II open-label clinical study for patients with myxoid liposarcoma with a (12;16) translocation. The study is intended to assess the safety and efficacy of SML's experimental drug product, brostallicin. The trial will also be supported by the Sarcoma Foundation of America (SFA).

Pharmatech will manage this sarcoma trial using its innovative Just-In-Time(TM) (JIT) approach. This streamlined approach was created to increase enrollment in clinical trials for rare cancer disease indications with narrow patient populations. The study sponsor does not open the trial at the site level until a potential patient is identified through basic standard of care procedures, thus saving time, money, and effort for both the sites and the sponsors. Patient enrollment, through Just-In-Time, is further increased because a protocol can be rolled out to a large number of qualified Research Network sites with minimal expense of time and capital.

The SML trial allowed for the formation of a partnership between Pharmatech and the Sarcoma Foundation of America. The union of the two organizations helps create awareness for the Foundation's Sarcoma Patient Registry program. The Registry allows patients to call into the Foundation to sign up for participation in the Registry program. If they consent, then they are notified by the Foundation if a current or future trial fits their specific disease indications. Matthew Alsante, Executive Director, Sarcoma Foundation of America, states, "The collaboration allows for a superior coordination among key players in the clinical trial process. The patients come to the Foundation through our sophisticated Registry. The Foundation takes the incidence data from the Registry to communicate directly with the patients about the clinical trials available to them through partnerships with research management groups such as Pharmatech."

About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research, while protecting patient safety. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through organized research networks, the Company focuses on access to clinical trials for patients and clinical investigators. The Network model provides a foundation for the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech, please visit

About Systems Medicine LLC

Systems Medicine, LLC (SML), develops oncology products by integrating predictive cellular pharmacogenomics ("genomics") with world-class clinical and regulatory expertise. This allows SML to develop patient-selective therapies by defining the context of vulnerability of cancer and treating only those patients most likely to respond to specific drugs or drug combinations. For more information on SML and the products that SML has in development, please visit

About the Sarcoma Foundation of America

The mission of the Sarcoma Foundation is to act as an advocate for increased research to find new and better therapies with which to treat patients with sarcoma. The Foundation has created a Sarcoma Patient Registry program that has the capability to match sarcoma patients into corresponding clinical trials. Please visit their website at for more information on the programs they have in place to help sarcoma patients.

SOURCE Pharmatech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
2. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
3. National Wrestling Coaches Association Teams Up With CSG/SportsCoatings(TM)
4. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
8. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
9. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
10. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
11. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
Post Your Comments:
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  InCarda ... the development and commercialization of therapies for cardiovascular conditions ... established a subsidiary business in Australia ... clinical trial in Australia in ... with leading investigators and medical centers in ...
(Date:12/1/2015)... SALT LAKE CITY , Dec. 1, 2015  Booth ... at booth #3506 during the annual meeting of the Radiological ... Chicago this year. Based in ... Imaging Components business of Varian Medical Systems (NYSE: VAR ... high voltage connectors, ionization chambers and solid state automatic exposure ...
(Date:12/1/2015)... -- Olea Sensor Networks, a leader in intelligent sensors and analytic software for sensor network-based systems, ... real-time data collection of vital signs. Photo ... ... ... ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... continuing medical education (CME), today announced that the first annual School of Gastrointestinal ... , “The prevention, detection and treatment of gastrointestinal cancers are undergoing transformational change, ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS ... 2015 Golden Bridge Business Awards under the New Products and Services category for ... based sample management software that helps labs organize data and track ...
(Date:12/1/2015)... CHICAGO (PRWEB) , ... December 01, 2015 , ... ... risk quantification and optimization of adjunctive imaging is the focus of numerous abstracts ... (RSNA) meeting, November 29-December 4, 2015. Nine abstracts highlight the use of ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
Breaking Medicine News(10 mins):